Liquid biopsy technology a ‘major advance’ but still requires validation

NEW ORLEANS — David Polsky, MD, PhD, professor of dermatology and pathology at NYU School of Medicine and NYU Langone Medical Center, offers insights into advances in liquid biopsy.

The ability to sample plasma can dramatically improve the ability to understand genetic alterations in solid tumors, Polsky said. Findings can help identify resistance mutations in patients who may be failing initial therapy and allow clinicians to change therapies earlier in the treatment course.

“This is a major advance that I think is getting closer to clinical practice, as more laboratories are employing newer technologies that have greater sensitivity and specificity,” Polsky told HemOnc Today. “There is a lot more work that needs to be done to validate these before they are ready for patient use, but I think we’ll certainly see this become part of patient management in the next several years.”

Leave a Reply

Your email address will not be published. Required fields are marked *